Sophie Schmitz attended world orphan drug congress

Many rare disease patients lay their hope in gene-therapy development. However, recent experience with Glybera (uniQure) has shown difficulties faced in the launch and access. During the World Orphan Drug Congress in Washington this month, Partners4Access had the opportunity to get latest insights from a German sickness fund that reimbursed Glybera and the CEO of…